(Albany, USA) DelveInsight’s ‘Obesity Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Obesity therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Obesity pipeline domain.
For Obesity emerging drugs, the Obesity pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Obesity Pipeline Report
- DelveInsight’s Obesity Pipeline analysis depicts a robust space with 100+ active players working to develop 130+ pipeline therapies for Obesity treatment.
- The leading Obesity companies include 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others are evaluating their lead assets to improve the Obesity treatment landscape.
- Key Obesity pipeline therapies in various stages of development include Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others.
- In May 2023, the FDA issued a warning concerning compounded versions of the drug semaglutide, which is licensed for the treatment of diabetes and obesity.
- In December 2022, Amgen announced new Phase I data from AMG 133. This first-in-human study was designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of AMG 133 in people with obesity and without diabetes (NCT04478708).
- In December 2022, Poolbeg Pharma, a clinical-stage infectious disease company, acquired the exclusive license from InsuCaps to use its proprietary microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes, and diabetes.
Request a sample and discover the recent breakthroughs happening in the Obesity pipeline landscape @ Obesity Pipeline Outlook
Obesity Overview
Obesity is a chronic medical condition characterized by an excessive accumulation of body fat, which can have significant negative effects on an individual’s overall health. One of the most common symptoms of obesity is weight gain, often accompanied by an increase in body mass index (BMI). Other obesity symptoms may include breathlessness, fatigue, joint pain, and reduced mobility. The diagnosis of obesity usually involves a comprehensive assessment that includes measuring BMI, waist circumference, and evaluating the individual’s medical history. In some cases, additional tests such as blood tests, imaging studies, and assessments of metabolic health may be conducted to determine the extent of the condition and associated health risks.
The treatment of obesity typically involves a multifaceted approach. Lifestyle modifications, including dietary changes and increased physical activity, are often recommended as the initial step. This may involve adopting a balanced and nutritious diet, reducing calorie intake, and engaging in regular exercise. In some cases, behavior therapy, counseling, and support groups can also be helpful.
Find out more about Obesity medication @ New Drug for Obesity
Obesity Treatment Analysis: Drug Profile
RZL-012: Raziel Therapeutics
RZL-012, an injectable medication for aesthetics and fat issues, is being developed by Raziel Therapeutics, a clinical-stage pharmaceutical company. A single injection of RZL-012 into subcutaneous fat leads to a considerable and sustained reduction in fat volume. RZL-012 is a unique synthetic small molecule that, when injected into subcutaneous fat, destroys fat cells. It is the first and only injectable medicine that decreases Lipomas in Dercum’s disease considerably and sustainably, lowering abdominal fat volume (body contouring) and submental fullness. RZL-012 inhibited fat cell formation and storage in vitro tests. RZL-012 is supplied through a series of injections given in a single session. Raziel Therapeutics currently evaluating RZL-012 in Phase II clinical trial for obesity.
Tirzepatide: Eli Lilly and Company
Tirzepatide is a once-weekly GIP receptor and GLP-1 receptor agonist that combines the activities of both incretins into a single new chemical. GIP is a hormone that may help GLP-1 receptor agonists work better. GIP reduces food intake while increasing energy expenditure in preclinical models, resulting in weight loss. When combined with GLP-1 receptor agonism, it may have a stronger impact on metabolic dysregulation markers such as body weight, glucose, and lipids. Tirzepatide is currently in Phase III development for individuals with obesity or overweight who have weight-related comorbidities, and it is also being reviewed by the FDA as a therapy for adults with type 2 diabetes.
Key Obesity Therapies and Companies
- Semaglutide oral: Novo Nordisk
- Tirzepatide: Eli Lilly and Company
- RZL-012: Raziel Therapeutics
- EMP16: Empros Pharma
- DD01: D&D Pharmatech
- ZP 8396: Zealand Pharma
- ERX-1000: ERX Pharmaceuticals
Learn more about the novel and emerging Obesity pipeline therapies @ Obesity Clinical Trials
Obesity Therapeutics Assessment
- By Product Type
-
- Monotherapy
- Combination Therapy
- By Stage
-
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- By Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Scope of the Obesity Pipeline Report
- Coverage: Global
- Key Obesity Companies: 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others.
- Key Obesity Pipeline Therapies: Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others.
Dive deep into rich insights for drugs used for Obesity treatment; visit @ Obesity Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Obesity Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Obesity Pipeline Therapeutics |
| 6. | Obesity Pipeline: Late Stage Products (Phase III) |
| 7. | Obesity Pipeline: Late Stage Products (Phase III) |
| 8. | Obesity Pipeline: Mid-Stage Products (Phase II) |
| 9. | Obesity Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Obesity therapy in the pipeline, reach out @ Obesity Medication
Related Reports
Obesity Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the obesity epidemiology trends.
Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, among others.
Hypothalamic Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others.
Hypothalamic Obesity Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others.
HET Obesity/POMC Deficiency Obesity Pipeline
HET Obesity/POMC Deficiency Obesity Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others.
HET Obesity/POMC Deficiency Obesity Market
HET Obesity/POMC Deficiency Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others.
Other Trending Reports
Bronchial Spasm Market | Meningioma Market | Necrotizing Enterocolitis Market Hyperhidrosis Market |Bacterial Meningitis Market | Anaphylaxis Market | Neurostimulation Devices Market | Intracranial Pressure Monitoring Devices Market | Acute Pharyngitis Market | Hepatitis B Virus Market | Thymic Carcinoma Market | Bladder Cancer Market | Spasticity Market | Interbody Cages Market | Helicobacter Pylori Infection Market | Intravenous Immunoglobulin Market | Opioid Induced Constipation Market | Ophthalmic Imaging Equipment Market | Epilepsy Market | Pharmaceutical Consulting Companies | Acquired Immunodeficiency Syndrome Market | Image Guided Surgery Devices Market | Androgenetic Alopecia Market | Acute Lung Injury Market | Astigmatism Market | Familial Primary Pulmonary Hypertension Market | Progressive Multifocal Leukoencephalopathy Market
Related Healthcare Services
- Healthcare Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187